
    
      To perform this registry, every patient diagnosed with AML in the participant institutions,
      regardless type of AML and treatment administered, must be reported. It will be required to
      registry the main characteristics of the patients and AML at diagnosis, as cytomorphologic,
      immunophenotypic, and cytogenetic results, according to the habitual practice of the centers.
      The treatment which has been administered by every center of the PETHEMA Group, even when it
      is considered as supportive care, and evolution of the disease will also be reported (relapse
      o death). PETHEMA Group will input all the reported information in data bases
    
  